Oral small molecule GLP-1 receptor agonist
Danuglipron 120 mg oral twice daily
DANU_PO_120MG_BID
Related
- All doses pooled: Danuglipron tablet
- Danuglipron 200 mg oral twice daily
- Danuglipron 80 mg oral twice daily
- Danuglipron 140 mg tablet twice daily
- Danuglipron 40 mg oral twice daily
- Danuglipron 160 mg oral twice daily
- Danuglipron 2.5 mg tablet twice daily
- Danuglipron 10 mg tablet twice daily
- Danuglipron 3 mg tablet
- Danuglipron 10 mg tablet
- Danuglipron 30 mg tablet
- Danuglipron 100 mg tablet
- Danuglipron 300 mg tablet
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.71 (0.01 to 55.87) | 0.42 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.22 (0.34 to 31.91) | 0.39 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.77 (0.40 to 19.34) | 0.31 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.58 (0.05 to 4.86) | 0.63 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 4.94 (1.93 to 13.70) | 0.18 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 9.28 (3.30 to 31.62) | 0.12 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 23.90 (6.17 to 123) | 0.05 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.77 (0.83 to 10.34) | 0.29 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 1.49 (0.08 to 21.90) | 0.52 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 0.50 (0.01 to 23.89) | 0.61 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.89 (0.05 to 14.56) | 0.46 |
Trials
- NCT03985293A 16-WEEK, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF-06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE2020 · 412 randomized · 16 weeks
- NCT04552470AN 8-WEEK PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TWICE DAILY PF-06882961 ADMINISTRATION IN JAPANESE ADULTS WITH TYPE 2 DIABETES MELLITUS2020 · 37 randomized · 8 weeks